Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vijay Modur

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Kidney Medicine|October 7, 2022
The STAGED-PKD 2-Stage Adaptive Study With a Patient Enrichment Strategy and Treatment Effect Modeling for Improved Study Design Efficiency in Patients With ADPKDRonald D Perrone, Ali Hariri, Pascal Minini, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 19, 2022
Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical TrialRonald T Gansevoort, Ali Hariri, Pascal Minini, et al.
Journal of Alzheimer'S Disease : JAD|November 14, 2014
Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohortJeffrey L Seeburger, Daniel J Holder, Marc Combrinck, et al.
Clinical Chemistry|March 9, 2013
Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scaleHelen E White, John Hedges, Israel Bendit, et al.
Blood|August 4, 2010
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)Timothy P Hughes, Andreas Hochhaus, Susan Branford, et al.
Molecular Genetics and Metabolism|December 8, 2022
Venglustat, an orally administered glucosylceramide synthase inhibitor: Assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension studyPatrick B Deegan, Ozlem Goker-Alpan, Tarekegn Geberhiwot, et al.
Human Molecular Genetics|July 5, 2020
Correction of cilia structure and function alleviates multi-organ pathology in Bardet-Biedl syndrome miceHervé Husson, Nikolay O Bukanov, Sarah Moreno, et al.
Journal of Lipid Research|January 30, 2026
Spatial Mapping of CoQ<sub>10</sub> Repletion by BPM31510 in a Genetic Mouse Model (Coq4<sup>F147C</sup>) of Coenzyme Q DeficiencyEliana Barriocanal-Casado, Sylwia A Stopka, Alba Pesini, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|April 3, 2026
BPM31510 Increases the CoQ Pool in Chemically Induced CoQ-Deficient Cells, CoQ-Deficient Patient Fibroblasts, and in Metabolically Active Murine TissuesJuan J Aristizabal-Henao, Sarah R Wessel, Sylwia A Stopka, et al.
Plos One|August 14, 2015
High Resolution Discovery Proteomics Reveals Candidate Disease Progression Markers of Alzheimer's Disease in Human Cerebrospinal FluidRonald C Hendrickson, Anita Y H Lee, Qinghua Song, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Kidney Medicine|October 7, 2022
The STAGED-PKD 2-Stage Adaptive Study With a Patient Enrichment Strategy and Treatment Effect Modeling for Improved Study Design Efficiency in Patients With ADPKDRonald D Perrone, Ali Hariri, Pascal Minini, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 19, 2022
Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical TrialRonald T Gansevoort, Ali Hariri, Pascal Minini, et al.
Journal of Alzheimer'S Disease : JAD|November 14, 2014
Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohortJeffrey L Seeburger, Daniel J Holder, Marc Combrinck, et al.
Clinical Chemistry|March 9, 2013
Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scaleHelen E White, John Hedges, Israel Bendit, et al.
Blood|August 4, 2010
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)Timothy P Hughes, Andreas Hochhaus, Susan Branford, et al.
Molecular Genetics and Metabolism|December 8, 2022
Venglustat, an orally administered glucosylceramide synthase inhibitor: Assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension studyPatrick B Deegan, Ozlem Goker-Alpan, Tarekegn Geberhiwot, et al.
Human Molecular Genetics|July 5, 2020
Correction of cilia structure and function alleviates multi-organ pathology in Bardet-Biedl syndrome miceHervé Husson, Nikolay O Bukanov, Sarah Moreno, et al.
Journal of Lipid Research|January 30, 2026
Spatial Mapping of CoQ<sub>10</sub> Repletion by BPM31510 in a Genetic Mouse Model (Coq4<sup>F147C</sup>) of Coenzyme Q DeficiencyEliana Barriocanal-Casado, Sylwia A Stopka, Alba Pesini, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|April 3, 2026
BPM31510 Increases the CoQ Pool in Chemically Induced CoQ-Deficient Cells, CoQ-Deficient Patient Fibroblasts, and in Metabolically Active Murine TissuesJuan J Aristizabal-Henao, Sarah R Wessel, Sylwia A Stopka, et al.
Plos One|August 14, 2015
High Resolution Discovery Proteomics Reveals Candidate Disease Progression Markers of Alzheimer's Disease in Human Cerebrospinal FluidRonald C Hendrickson, Anita Y H Lee, Qinghua Song, et al.
Pageof 3